Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
Maastricht University Medical Center
DEKA Biosciences
University Hospital, Ghent
Jules Bordet Institute